poisar

Stock

Spero Therapeutics, Inc. SPRO

$1.22+0.41%

Overview

SPRO market data

Price History

SPRO price chart · 3M
O
1.22
H
1.22
L
1.18
C
1.22
Vol
31,202.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$1.22
Previous Close
$1.21
Day High
$1.22
Day Low
$1.18
52 Week High
$3.07
52 Week Low
$1.09
7 Day Return
+0.00%
30 Day Return
+1.67%
90 Day Return
-56.91%
1 Year Return
-51.98%
Daily Notional Volume
$37.9K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
4.73
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$0.15
Diluted earnings per share over the trailing twelve months.
Beta
1.49
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
24.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.08 – $3.08
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $72.1M · P/B 2.22 · P/S 1.18.

Company News

8 captured
8-K filing — Spero Therapeutics, Inc. (SPRO)SEC EDGAR · Aug 12, 2026, 8:09 PM
Spero Therapeutics Q2 EPS $(0.16) Down From $(0.03) YoYBenzinga · Aug 12, 2026, 8:01 PM
Spero Therapeutics shares are trading lower. The company announced an exclusive license agreement with Innovent Biologics for SP001, a third‑gen Fc‑silent anti‑CD40L antibody.Benzinga · Jul 14, 2026, 5:12 PM
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L AntibodyGlobenewswire Inc · Jul 14, 2026, 11:00 AM
Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare RoyaltyBenzinga · Jul 14, 2026, 10:11 AM
Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-ChinaBenzinga · Jul 14, 2026, 10:09 AM
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIsBenzinga · Jun 17, 2026, 6:15 PM
GSK, Spero Therapeutics Announce FDA Approves Utebzi To Treat Complicated Urinary Tract InfectionsBenzinga · Jun 17, 2026, 3:30 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock
Spero Therapeutics, Inc. (SPRO) stock — price, valuation & news | Poisar